WO2005097227A1 - Biocompatible polyacrylate compositions for medical applications - Google Patents
Biocompatible polyacrylate compositions for medical applications Download PDFInfo
- Publication number
- WO2005097227A1 WO2005097227A1 PCT/US2005/010186 US2005010186W WO2005097227A1 WO 2005097227 A1 WO2005097227 A1 WO 2005097227A1 US 2005010186 W US2005010186 W US 2005010186W WO 2005097227 A1 WO2005097227 A1 WO 2005097227A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- poly
- biobeneficial
- heparin
- composition
- mixtures
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- This invention is directed to polymers used in medical applications, such as coatings for medical devices or implantable prostheses.
- the surface of devices already designed and manufactured from such materials can be made biocompatible, as well as hydrophilic and slippery, by properly designed coatings.
- the way has been opened to construct medical devices from conventional plastics and metals having the particular physical properties required, and then to apply suitable coatings to impart the desired properties to their surfaces.
- polymers can be usedto deliver biologically or pharmaceutically active agents to a treatment site.
- stents have been modified with polymers for local application of a therapeutic substance.
- systemic aclministration of medication often produces adverse or toxic side effects for the patient.
- Local delivery is a preferred method of treatment, because smaller total levels of medication are administered in comparison to systemic dosages, and this medication is concentrated at a specific site. Local delivery thus produces fewer side effects and achieves better results.
- a solution that includes a solvent, a polymer dissolved in the solvent, and a therapeutic substance dispersed in the blend is applied to the stent. The solvent is then allowed to evaporate, leaving on the stent surface a coating of the polymer and the therapeutic substance impregnated in the polymer. Once the stent has been implanted at the treatment site, the therapeutic substance is released from the polymer coating over time.
- coated stents improves pharmacological treatment of the patient and improves biocompatibility of the medical device in the patient, coatings can still be improved.
- the embodiments of the present invention provide stent coatings that have these and other advantages.
- a composition including a biologically compatible structural component such as a linear acrylic homopolymers, linear acrylic copolymers, or styrene and a biobeneficial component comprising copolymers having a bioactive or biobeneficial moiety.
- the biobeneficial component can also comprise an acrylate moiety.
- the composition can be used as a coating in medical applications such as for a stent.
- the composition can also be used for delivery of a drug or therapeutic substance.
- the mass ratio between the structural component and the biobeneficial component can be between about 99:1 and about 1:1, more narrowly, between about 19:1 and about 9:1, such as about 3:1.
- acrylic homopolymers and linear acrylic copolymers that can be used for making the structural component include poly(methylmethacrylate), poly(ethylmethacrylate), poly(n-propyl methacrylate), poly(isopropylmethacrylate), poly(n- butylmethacrylate), poly(n-laurylmethacrylate), poly(2-hydroxyethylrnethacrylate), poiy(me y]methacrylate-co-2-hydroxyethyl methacrylate), poly(n-butylmethacrylate-co-2- hydroxyethyl methacrylate), and mixtures thereof.
- a copolymer comprising the biobeneficial component can be a block copolymer having the formula
- mi, ni, pi, ri, m 2 , n 2 , p 2 , and r 2 are all integers, wherein each of mi, m 2 , pi, and p 2 can be 0 or greater; each of m, n 2 , n, and r 2 can be greater than 0, and n and r 2 can be the same or different; mi and m 2 can be the same or different; ni and n 2 can be the same or different; and pi and p 2 can be the same or different; X can be hydrogen or methyl group; each of R and Ri, independently, can be methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, lauryl, or 2-hydroxy ethyl; and Q can be a fragment that provides the biobeneficial properties.
- Q fragments can be derived from poly(alkylene glycols), superoxide dismutate-n-timetics (SODm), diazenium diolate-type nitric oxide donors, polycationic peptides, polysaccharides, pyrrolidone, vitamin E, sulfonated dextrane, ⁇ -phenoxyethanol. N,N-dimemylamino-2-ethanol, mannose-6- phosphate, sulfonic acid and derivatives of sulfonic acid, among others.
- This invention also relates to a medical article fabrication method.
- the method comprises preparing a polymeric combination comprising a structural component including linear acrylic homopolymers or linear acrylic copolymers and a biobeneficial component comprising copolymers having an acrylate moiety and a biobeneficial moiety and forming a medical article from the combination or depositing the combination on a medical article.
- the biobeneficial component can include random, block, graft, or brush copolymers.
- One method of making block copolymers includes copolymerizing an acrylate and a biobeneficial monomer using of living, free-radical copolymerization with initiation-transfer-agent termination of the living chains.
- block copolymer and “graft copolymer” follow the teixninology used by the International Union of Pure and Applied Chemistry (IUPAC).
- Block copolymer refers to a copolymer containing a linear arrangement of blocks. A block is defined as a portion of a polymer molecule in which the monomeric units have at least one constitutional or configurational feature absent from adjacent portions.
- Graft copolymer refers to a polymer composed of mac- romolecules with one or more species of blocks connected to the main chain as side chains, having constitutional or configurational features different than those in the main chain.
- AB-block copolymer is defined as a block copolymer having moieties A and B arranged according to the general formula - ⁇ [A - ]m - [B]n ⁇ x - , where each of m, n, and x is a positive integer, and m can be ⁇ 2, and n can be - 2.
- ABA-block copolymer is defined as a block copolymer having moieties A and B arranged according to the general formula - ⁇ [A - ]m - [B - ]n - [A]p ⁇ x - , where each of m, n, p, and x is a positive integer, and m can be $s 2, and n can be - 2, and p can be ⁇ 2.
- ABS-block copolymer is defined as a block copolymer having moieties A, B, and C arranged according to the general formula - ⁇ [A - ]m - [B - ]n - [C]p ⁇ x - where each of m, n, p, and x is a positive integer, and m can be i ⁇ 2, and n can be j 2, and p can i 2.
- the ABA-block copolymer can be named poly A-block-co-poly B-block-co-poly A-block copolymer
- the ABC-block copolymer can be named poly A-block-co-poly B-block-co-poly C-block copolymer
- the AB-block co-polymer can be named poly A-block-co-poly B-block copolymer.
- Blocks A, B, and C can be longer than three blocks and can be alternating or random.
- copolymer encompasses for purposes of this disclosure a polymer with two or more constituent monomers and does not imply a polymer of only two monomers.
- brush copolymer includes two copolymer types.
- the first type includes copolymers with some branch points with, in some embodiments, functionality greater than three.
- the second type includes the following structure:
- the horizontal chain symbolizes the polymer backbone chain, for example, a poly(n-butyl methacrylate) chain, and vertical chains symbolize side chains connected to the backbone chain.
- a polymer that can form side chains is poly(ethylene glycol).
- a "linear polymer” is a polymer that does not contain branches with a chain length greater than 3.
- a thermoplastic polymer is a polymer that may not be capable of forming cross-links, and consequently does not form crosslinks when heated, whether with or without a crosslinking catalyst.
- a thermoplastic polymer that includes cross linking fragments can be crosslinked. Examples of such fragments include ⁇ -bonds and functional groups, such as amino, epoxy, urethane, etc.
- Non crosslinking thermoplastic polymers soften and fuse when heated and solidify when cooled. This melt-freeze cycle can be repeated many times without substantially chemically altering the polymer. Also, a solvent-soluble thermoplastic polymer remains soluble after any number of melt-freeze cycles.
- Linear thermoplastic polymers Polymers that are linear and thermoplastic are “linear thermoplastic polymers.”
- linear polymers or “thermoplastic polymer,” or “linear thermoplastic polymer” are used, in some embodiments these terms specifically exclude polymers that contain crosslinks.
- linear polymers and thermoplastic polymers are substantially free of crosslinked fragments; in some embodiments, completely free of crosslinked fragments.
- the composition can include a structural component comprising linear acrylic homopolymers or copolymers or styrene, which, in some embodiments can be thermoplastic; and a biobeneficial component comprising copolymers having an acrylate moiety and a biobeneficial or bioactive moiety.
- the structural component and the biobeneficial component can be blended.
- the two components can be bonded, linked such as by a linking agent, conjugated or cross-linked.
- the mass ratio between the structural component and the biobeneficial component can be between about 99:1 and about 1:1, more narrowly, between about 19 : 1 and about 9 : 1 , for example, about 3 : 1.
- the mass ratio ' between the acrylate moiety and the biobeneficial moiety can be between about 99:1 and about 1:1, more narrowly, between about 19:1 and about 9:1, for example, about 3:1.
- the biologically compatible structural component can comprise linear acrylic homopolymers or copolymers, for example.
- the homo- and co-polymers can be thermoplastic.
- the structure of linear acrylic homopolymers and copolymers can be illustrated by general Formula I.
- PBMA poly (n-butyl methacrylate)
- PBMA is a thermoplastic homopolymer.
- linear acrylic copolymers suitable for the structural component include poly(methylmethacrylate-Co-2- hydroxyethyl methacrylate) (PMMA-HEMA) and poly(n-butylmethacrylate-co-2-hydroxyethyl methacrylate) (PBMA-HEMA).
- PMMA-HEMA poly(methylmethacrylate-Co-2- hydroxyethyl methacrylate)
- PBMA-HEMA poly(n-butylmethacrylate-co-2-hydroxyethyl methacrylate)
- Other homopolymers or copolymers described by Formula I, or mixtures thereof can be also used.
- the biobeneficial component can comprise a copolymer having at least one acrylate moiety and at least one biobeneficial moiety.
- random, block, graft or brush copolymers can be used.
- some constituent units of the copolymers can include an acrylate moiety while other constituent units can include a biobeneficial moiety.
- Examples of useful block copolymers include AB-, ABA-, BAB-, ABC-, or ABCBA block copolymers.
- AB-, ABA- or BAB-block copolymers either moiety A or B can be an acrylate moiety, and the other moiety can be a biobeneficial moiety.
- B, or C, or any two of A, B, and C can be an acrylate moiety or moieties, while the remaining moiety or moieties can be biobeneficial.
- X can be hydrogen or methyl group
- each of R and Ri can be methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, lauryl, 2-hydroxyethyl;
- B-units are biobeneficial moieties, which can be attached to the backbone of the block copolymer in a variety of ways, for example by an acyl group or by a methylene bridge.
- Q makes the B-units biobeneficial
- the structure of the random copolymer is generally similar to the structure shown in Formula II, except the A-, B-, and C-units in the random copolymer are randomly distributed.
- Examples of Q providing biobeneficial properties to the B-units include those derived from poly(alkylene glycols) such as poly(ethylene glycol), poly(propylene glycol), poly(tetramethylene glycol), poly(ethylene glycol-co-propylene glycol), or poly(ethylene oxide- co-propylene oxide), superoxide dismutate-mimetics (SODm), diazenium diolate type nitric oxide donors, polycationic peptides, polysaccharides, for example, heparin or heparin derivatives, pyrrolidone, vitamin E, sulfonated dextrane, ⁇ -phenoxyethanol, N,N-dimemylamino-2-ethanol, mannose-6-phosphate, sulfonic acid and derivatives of sulfonic acid such as propanesulfonic acid, 2-methyl-l -propanesulfonic acid, benzenesulfonic acid, and 3-methoxy-2- hydroxypropanesulfonic acid
- SODm Superoxide dismutate-mimetics
- SODm are oxidoreductase-based complexes that contain of copper, iron, or manganese cations.
- SODm are major intracellular enzymes that protect the cell from oxygen toxicity by dismutating the superoxide, radical O 2 -, to oxygen and hydrogen peroxide.
- a hepta coordinated, manganese-based SODm, manganese(II) dichloroaminoethyl- thiolated pentaazatetracyclohexacosatriene (SOD-40470) (manufactured by Metaphore Pharmaceuticals, Inc., St. Louis, Missouri) is one example of SODm that can be used in B-units. Other types of SODm can also be used, if desired.
- Diazeniumdiolate-type nitric-oxide donors are adducts of nitric oxide (NO) with nucleo- philic amines.
- NO nitric oxide
- Diazenium diolates also known as NONOates, are highly biologically compatible and possess valuable medicinal properties. In slightly acidic medium, they spontaneously release NO, which has excellent therapeutic properties.
- NONOates nitric oxide
- diolate that can be used for making B-units is an aliphatic NONOate, 1,3-propanediamine, N- ⁇ 4-[l-(3- aminopropyl)-2-hydroxy-2-nitrosohydrazino] butyl ⁇ -diazen-l-ium-l,2-diolate, also known as speramine diazenium diolate (SDD) and having the formula NH2-(CH 2 ) 3 -N[N+(O)-(N-OH)]- (CH 2 ) 4 -NH-(CH 2 ) 3 -NH 2 .
- SDD is manufactured by Molecular Probes, Inc., Eugene, Oregon.
- other diazenium diolate-type NO donors can be used.
- MAHMA-NO and DETA-NO can be obtained from Cayman Chemical Co., Ann Arbor, Michigan.
- poly(L-arginine) includes L-, D-, and/or D,L-arginine in both its polymeric and oligomeric form.
- Heparin derivates can be used for the B-units, as well. Heparin is derived from a mixture of sulfated polysaccharide chains based on D-glucosamine and D-glucoronic or L-iduronic acid. In some embodiments, "heparin derivative" include any functional or structural variation of heparin.
- heparinoids include heparinoids, heparin having a hydrophobic counterion, heparan sulfate, alkali metal or alkaline-earth metal salts of heparin, for example, sodium heparin (also known as hepsal or pularin), potassium heparin (formerly known as clarin), lithium heparin, calcium heparin (also known as calciparine), magnesium heparin (also known as cutheparine), low molecular weight heparin (also known as ardeparin sodium), and blends thereof.
- sodium heparin also known as hepsal or pularin
- potassium heparin formerly known as clarin
- lithium heparin lithium heparin
- calcium heparin also known as calciparine
- magnesium heparin also known as cutheparine
- low molecular weight heparin also known as ardeparin sodium
- heparin derivatives to specifically exclude any one or any combination of heparinoids, heparin having a hydrophobic counterion, heparan sulfate, alkali metal or alkaline-eartlh metal salts of heparin, sodium heparin (also known as hepsal or pularin), potassium heparin (formerly known as clarin), lithium heparin, calcium heparin (also known as calciparine), magnesium heparin (also known as cutheparine), or low molecular weight heparin (also known as ardeparin sodium).
- B-unit-suitable polysaccharides examples include glycosaminoglycans (or mucopolysaccharides) such as keratan sulfate, chondroitin sulfate, dermatan sulfate (also known as chondroitin sulfate B), hyaluronic acid, hyaluronates and blends thereof.
- glycosaminoglycans or mucopolysaccharides
- keratan sulfate such as keratan sulfate, chondroitin sulfate, dermatan sulfate (also known as chondroitin sulfate B), hyaluronic acid, hyaluronates and blends thereof.
- any monomer shown in Table 1 can be used.
- the biobeneficial moiety forming the random or block copolymer (B-units in Formula II) from unsaturated monomers or oligomers.
- the choice of the monomer or oligomer depends on the desired biological response.
- the biobeneficial moiety can be anti-restenotic or can ensure better blood compatibility, or can promote cell adhesion.
- Examples of the monomers or oligomers yielding antirestenotic moieties can be derived include acryloyl-, methacryloyl-, vinyl or allyl-modified adducts of SODm, acryloyl-, methacryloyl-, vinyl or allyl-modified NO donors examples of NO donors include DETA or speramine), acryloyl-, methacryloyl-, vinyl or allyl-modified adducts of phosphoryl choline, and acryloyl-, methacryloyl-, vinyl or allyl-modified polycationic peptides such as poly-L-arginine.
- Examples of monomers that can form the biobeneficial moiety include 2-acrylamido-2- methyl-1 -propanesulfonic acid, poly(ethylene glycol) methacrylate, 3-sulfopropyl acrylate, 3- sulfopropyl methacrylate, N-vinylpyrrolidone, vinylsulfonic acid, 4-styrenesulfonic acid and 3- allyloxy-2-hydroxypropanesulfonic acid. All monomers based on sulfonic acid can be either alkali metal salts (e.g., K+ or Na+) or acids.
- alkali metal salts e.g., K+ or Na+
- some examples of particular copolymers having that structure that can be used include poly(ethylene glycol)-block- poly(n-butylmethacrylate)-block-poly(ethylene glycol) (PEG-PBMA-PEG, an ABA block copolymer), or poly(n-butylmethacrylate)-block-poly(ethylene glycol)-block-poly(n- butylmethacrylate) (PBMA-PEG-PBMA, a BAB-block copolymer).
- the molecular weight of the PEG units can be between about 500 and 30,000 Daltons, and the molecular weight of the PBMA units can be between about 500 and 30,000 Daltons.
- the random or block copolymers represented by Formula II can be obtained by common synthetic methods, for example, by radical copolymerization of monomers forming A-, B-, and/or C-units in bulk, solution, suspension, or emulsion with of suitable initiators.
- standard radical-polymerization initiators can be used.
- suitable initiators include azobis(isobutyronitrile) and 2,2-dimethoxy-2-phenol ace- tophenone.
- the photosensitizer, benzophenone can be added to 2,2-dimethoxy-2- phenol acetophenone.
- the in- ferter process uses an initiator that exhibits thermal photolytic free-radical decomposition.
- these initiators are benzyl-N,N-diet ylditbiocarbamate (BDC) or p-xylylene-N,N- diethyldithiocarbamate (XDC).
- BDC is a toluene derivative and has the formula shown in Formula III:
- Formula III XDC is a p-xylene derivative and has the formula shown in Formula IN:
- BDC or XDC initiators can be synthesized by combining sodium ⁇ , ⁇ - diethyldithiocarbamate with benzyl bromide in an anhydrous methanol solution. Some embodiments use an equimolar or substantially equimolar ratio. The mixture can be stirred for about 24 hours at about room temperature to yield BDC solution. The solution can be removed by evapo- rating methanol at a reduced pressure or by vacuum distillation.
- XDC The synthesis of XDC is similar, except, ⁇ , ⁇ -dibromo-p-xylene replaces benzyl bromide, and the molar ratio between sodium N,N-diethyldithiocarbamate and ⁇ , ⁇ -dibromo-p-xylene can rise to about 1 :2.3. This yields XDC, which can be purified by recrystallization in methanol.
- compositions can be added to composition.
- This can be in a form of a simple blend or a linking, conjugation or bonding process.
- Representative examples include p ⁇ ly(ethylene-co-vinyl alcohol), poly(hydroxyvalerate), poly(L-lactic acid), poly- caprolactone, poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co- valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(D,L-lactic acid), poly(glycolic acid-co-trimethylene carbonate), poly(glycerol-sebacate), polyphosphoester, polyphosphoester urethane; poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), copoly(ether-esters) (e.g.
- PEO/PLA polyalkylene oxalates, polyphos- phazenes, biomolecules (such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid), polyurethanes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, vinyl halide polymers and copolymers (such as poiyvinyl chloride), polyvinyl ethers (such as polyvinyl methyl ether), polyvinylidene halides (such as polyvinylidene fluoride and polyvinylidene chloride), polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics (such as polystyrene), polyvinyl esters (such as polyvinyl acetate), copolymers of vinyl monomers with each other and olefins (such as ethylene-methyl methacrylate copolymers, acrylonitrile-s
- a drug or therapeutic agent can serve as the optional component.
- the therapeutic agent can include any substance capable of exerting a therapeutic, diagnostic or prophylactic effect for a patient.
- the therapeutic agent may include small molecules, peptides, proteins, oligonucleotides, and the like.
- the therapeutic agent could be designed, for example, to inhibit the vascular-smooth-muscle-cell activity. It can inhibit abnormal or inappropriate migration or proliferation of smooth muscle cells.
- therapeutic substances that can be used include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof (manufactured by Sigma- Aldrich of Milwaukee, Wisconsin, or COSMEGEN available from Merck).
- actinomycin D examples include actinomycin, actinomycin IN, actinomycin II, actinomycin XI, and actinomycin Cl.
- the active agent can also fall under the genus of antineoplastic, antiinflammatory, antiplatelet, anticoagulant, antifibrin, anti- thrombin, antimitotic, antibiotic, antiallergic and antioxidant substances.
- anti- neoplasties and/or antimitotics include paclitaxel (e.g. TAXOL® by Bristol-Myers Squibb Co., Stamford, Conn.), docetaxel (e.g.
- Taxotere® from Aventis S.A., Frarj furt, Germany
- meth- otrexate azathioprine
- vincristine vinblastine
- fluorouracil doxorubicin hydrochloride
- doxorubicin hydrochloride e.g. Adriamycin® from Pharmacia & Upjohn, Peapack ⁇ .J.
- mitomycin e.g. Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.
- antiplatelets examples include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Ilb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as ANGIOMAX (Biogen, Inc., Cambridge, Mass.).
- cytostatic or antiproliferative agents examples include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisi- nopril (e.g.
- an antiallergic agent is permirolast potassium.
- Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, tacrolimus, dexamethasone, and rapamycin and structural derivatives or func- tional analogs thereof, such as 40-O-(2-hydroxy)ethyl-rapamycin (known by the trade name of ENEROLIMUS available from ⁇ ovartis), 40-O-(3-hydroxy)propyl-rapamycin. 40-O-[2-(2- hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.
- a medical device can be made from the composition or coated with the composition.
- the device can include any medical device, preferably implantable medical devices such as catheters, balloons, guidewires, stents, grafts, stent-grafts, intra-ocular lenses, artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, and endocardial leads.
- implantable medical devices such as catheters, balloons, guidewires, stents, grafts, stent-grafts, intra-ocular lenses, artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, and endocardial leads.
- the underlying structure of the device can be of virtually any design.
- the device can be made of a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), "MP35 ⁇ ,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, plati- num-iridium alloy, gold, magnesium, or mixtures thereof.
- ELGILOY cobalt chromium alloy
- stainless steel 316L
- MP35 ⁇ "MP20N”
- ELASTINITE Ni- num-iridium alloy
- tantalum nickel-titanium alloy
- plati- num-iridium alloy gold, magnesium, or mixtures thereof.
- MP35N and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co. of Jenkintown, Pennsylvania.
- MP35N consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum.
- MP20N consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum.
- Devices made from bioabsorbable or biostable polymers could also be used with, the embodiments of the present invention.
- the device is a bioabsorbable or erodable stent.
- the embodiments of the present invention can be used as a coating for a stent.
- the stent can include a primer layer; a drug-polymer layer (also referred to as "reservoir” or “reservoir layer”) or alternatively a polymer-free drug layer; a topcoat layer; and a finishing coat layer.
- the top coat layer or the primer layer can be free from any drugs. Some drugs may migrate into these layers during or subsequent to the manufacturing process.
- Any one or combination of the coating layers can be formed on the stent by dissolving the composition of the present invention in a solvent, or a solvent mixture, and applying the solution to the stent by spraying or immersion. The removal of the solvent can produce a dry coating. Elevating the temperature can accelerate drying.
- the complete coating can be annealed between about 40 and about 150 °C for about 5 to about 60 minutes, if desired, to improve the coating's thermal stability.
- the drug can be combined with the polymer solution.
- a stent having the above-described coating is useful for a variety of medical procedures, including, by way of example, treatment of obstructions caused by tumors in bile ducts, esophagus, trachea/bronchi and other biological passageways.
- a stent having the above-described coating is particularly useful for treating occluded regions of blood vessels caused by abnormal or inappropriate migration and proliferation of smooth muscle cells, thrombosis, and restenosis.
- Stents may be placed in a wide array of blood vessels, both arteries and veins. Representative examples of sites include the iliac, renal, and coronary arteries.
- the compositions of the invention can be used for the treatment of a variety of disorder in mammals including atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anasto- motic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, cancer as well as other disorders.
- Embodiments of the present invention are further illustrated by the following examples. Throughout the examples section and throughout the specification and claims, for economy of language "solvent" means pure solvents and systems of mixtures of solvents.
- a solution comprising a blend of monomers, a thermal initiator, and a solvent can be prepared by thoroughly mixing the following components:
- AIBN is an example of a useful thermal initiator. Those having ordinary skill in the art know of others, for example, peroxide-type initiators, as well.
- Thermal radical copolymerization can be carried between about 50 and about 60 °C for an amount of time, for example, for about 2 hours.
- the process can be carried out in an inert atmosphere, such as that created by bubbling an inert gas such as nitrogen or argon through the solution for about 30 minutes.
- AIBN decomposes, releasing nitrogen and generating free radicals.
- P(MMA-BMA-PEGMA) One possible structure of P(MMA-BMA-PEGMA) is shown by Formula N:
- P(MMA-BMA-PEGMA) can be obtained with a UN-initiated process.
- a solution comprising a blend of BMA, MMA and PEGMA in benzene can be prepared, as described above.
- a photoinitiator e.g., 2,2-dimethoxy-2-phenol acetophenone
- the amount of 2,2-dimethoxy-2-phenol acetophenone can be the same as described above.
- the solution can then be exposed to UV radiation for about 10 minutes at a wavelength of 360 nm while being stirred yielding P(MMA-BMA- PEGMA), Formula V.
- n-butylmethacrylate (BMA) can be dissolved in 2-butanone and an initiator, XDC, can be added.
- Component amounts are summarized in Table 2.
- the solution of BMA and XDC in 2-butanone can be placed into a borosilicate vial, purged with dry nitrogen for about 30 minutes, and the vial can be sealed.
- the contents can be UV irradiated at a wavelength of about 310 and about 400 nm, for about 12 hours.
- the vial can then be opened, and the contents can be added dropwise to ethanol -76°C.
- poly(butylmethacrylate)-XDC adduct PBMA-XDC
- PBMA-XDC poly(butylmethacrylate)-XDC adduct
- PBMA-XDC can be combined with acryloyl poly(ethylene glycol) (acryloyl-PEG) and 2-butanone in the amounts shown in Table 3.
- Acryloyl-PEG is a PEG esterification product of acrylic acid and has a Formula VI:
- a low molecular weight acryloyl-PEG oligomer, with a number-average molecular weight (Mn) of about 375, can be used. This corresponds to a value of x in Formula VI of about 7.
- the blend of PBMA-XDC, acryloyl-PEG and 2-butanone can be UV irradiated at a wavelength of about 310 to about 400 nm, for about 12 hours.
- the vial can then be opened, and the contents can be added dropwise to water and vigorously stirred at about 70°C for about 2 hours, evaporating the 2-butanone and suspending the poly(acryloyl-PEG)-block-n-butylmethacrylate- block-acryloyl-PEG)-XDC.
- the suspension can be cooled to room temperature, and the precipitate can be collected and vacuum dried using a vacuum funnel.
- the adduct is then hydrolyzed in the presence of a strong base to remove XDC.
- poly(acryloyl-PEG-block-n- butylmethacrylate-block-acryloyl-PEG) (PEG-PBMA-PEG), which is a ABA-block copolymer having Formula VII, can be precipitated.
- PBMA-XDC a PBMA-XDC adduct can be obtained from Example 2.
- PBMA-XDC can be combined with acryloyl poly(ethylene glycol) (acryloyl-PEG) and 2-butanone in the amounts shown in Table 4.
- a low-molecular- weight acryloyl-PEG oligomer, with a number-average molecular weight (Mn) of about 375, can be used. This corresponds to a value of x in Formula VII of about 7.
- the blend of PBMA-XDC, acryloyl-PEG and 2-butanone can be UV radiated at a wavelength of about 310 to about 400 nm, for about 12 hours.
- the vial ' can then be opened, and the contents can be added dropwise to water and vigorously stirred at a about 70 °C for about 2 hours, evaporating the 2-butanone and suspending the poly(n-butylmethacrylate-block-acryloyl-PEG)-XDC.
- the suspension can be cooled to room temperature and the precipitate can be collected and vacuum-dried.
- the adduct is then hydrolyzed in the presence of a strong base to remove XDC, yielding poly(n-butylmethacrylate-block-acryloyl-PEG) (PBMA-PEG), which is an AB-block copolymer having Formula VIII.
- PBMA-PEG poly(n-butylmethacrylate-block-acryloyl-PEG)
- n-butyl methacrylate (BMA), acryloyl-PEG, and acryloyl- phosphoryl choline can be mixed and dissolved in 2-butanone.
- Phosphoryl choline is also known as N,N,N-trimethyl-2-aminoethyl phosphonate.
- Acryloyl-phosphoryl cho-line is an acrylic derivative of phosphoryl choline having the Formula IX:
- the blend of BMA, acryloyl-PEG, acryloyl-phosphoryl choline and 2-butanone can be UV radiated at a wavelength of about 310 to about 400 nm, for about 12 hours.
- the vial can then be opened, and the contents can be added dropwise to water and vigorously stirred at a about 70 °C for about 2 hours, evaporating the 2-butanone and suspending the poly(n-butylmethacrylate-co- acryloyl-PEG-co- acryloyl-phosphoryl choline).
- the suspension can be cooled to the room temperature, and the precipitate can be collected and vacuum dried.
- PBMA-PEG-PC poly(n- bu1ylmethacrylate-co-acryloyl-PEG-co-acryloyl-phosphoryl choline) (PBMA-PEG-PC)
- PBMA-PEG-PC poly(n- bu1ylmethacrylate-co-acryloyl-PEG-co-acryloyl-phosphoryl choline)
- a first composition can be prepared by mixing the following components:
- the first composition can be sprayed onto the surface of a bare 13 mm TETRA stent (available from Guidant Corporation), and dried to form a primer layer.
- a spray coater can be used having a 0.014 fan nozzle maintained at about 60 °C with a feed pressure of about 0.2 atm (about 3 psi) and an atomization pressure of about 1.3 atm (about 20 psi).
- the primer layer can be baked at about 80 °C for about 30 minutes, yielding a dry primer layer.
- the dry primer layer can contain about 60 ⁇ g of PBMA.
- a second composition can be prepared by mixing the following components:
- the second composition can contain about 600 ⁇ g of the mixture. It composition can be applied onto the dried primer layer to form a reservoir layer, using the primer layer's spraying techniques and equipment. This is followed by drying, e.g., by baking at about 50°C for about 2 hours, yielding a dry reservoir layer.
- a third composition can be prepared by mixing the following components:
- the third composition can be applied onto the dried reservoir layer to form a topcoat layer using the same spraying technique and equipment used for applying the primer layer and the reservoir layer.
- the wet topcoat layer can be dried and baked at about 50 °C for about 2 hours.
- the dry topcoat layer can contain about 200 ⁇ g of the PBMA-PEG block-polymer.
- a primer layer can be fabricated as described in Example 5.
- a first composition can be prepared by mixing the following components:
- the second composition can contain about 600 ⁇ g of the mixture. It can be applied onto the dried primer layer to form the reservoir layer as described in Example 5.
- a third composition can be prepared by mixing the following components:
- the third composition can be applied onto the dried reservoir layer to form a topcoat layer as described in Example 5.
- a primer layer can be fabricated as described in Example 5.
- a first composition can be prepared by mixing the following components:
- the second composition can contain a about 600 ⁇ g of the mixture.
- the composition is not necessarily a solution because Na heparin is not completely soluble in the solvent. It can be applied onto the dried primer layer to form the reservoir layer as described in Example 5.
- a third composition can be prepared by mixing the following components:
- the third composition can be applied onto the dried reservoir layer to form a topcoat layer as described in Example 5.
- a primer layer can be fabricated as described in Example 5.
- a first composition can be prepared by mixing the following components:
- the second composition can contain a about 600 ⁇ g of the mixture. It can be applied onto the dried primer layer to form the reservoir layer as described in Example 5.
- a third composition can be prepared by mixing the following components:
- the third composition can be applied onto the dried reservoir layer to form a topcoat layer as described in Example 5.
- a primer layer and a reservoir layer can be fabricated as described in Example 5.
- a composition can be prepared by mixing the following components:
- POLYACTIVE is a trade name of a family of poly(ethylene glycol)-block- poly(butyleneterephthalate)-block poly(ethylene glycol) copolymers (PEG-PBT-PEG) and is available from IsoTis Corp. of Holland.
- the grade of POLYACTIVE that can be used can have about 45 molar % units derived from PBT and about 55 molar % units derived from PEG.
- the molecular weight of the PEG units can be about 300 Daltons.
- the overall weight-average mo- lecular weight (Mw) of POLYACTIVE can be between about 75,000 Daltons and about 125,000 Daltons.
- composition can be applied onto the dried reservoir layer to form a topcoat layer as described in Example 5.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05730732.4A EP1748806B1 (en) | 2004-03-31 | 2005-03-25 | Biocompatible polyacrylate compositions for medical applications |
JP2007506403A JP5687815B2 (en) | 2004-03-31 | 2005-03-25 | Biocompatible polyacrylate composition for medical use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/815,421 US7758880B2 (en) | 2002-12-11 | 2004-03-31 | Biocompatible polyacrylate compositions for medical applications |
US10/815,421 | 2004-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005097227A1 true WO2005097227A1 (en) | 2005-10-20 |
Family
ID=34964190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/010186 WO2005097227A1 (en) | 2004-03-31 | 2005-03-25 | Biocompatible polyacrylate compositions for medical applications |
Country Status (4)
Country | Link |
---|---|
US (4) | US7758880B2 (en) |
EP (1) | EP1748806B1 (en) |
JP (2) | JP5687815B2 (en) |
WO (1) | WO2005097227A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006002399A2 (en) * | 2004-06-24 | 2006-01-05 | Surmodics, Inc. | Biodegradable implantable medical devices, methods and systems |
US8236338B2 (en) | 2004-07-13 | 2012-08-07 | The University Of Tennessee Research Foundation | Adhesive composition for carrying therapeutic agents as delivery vehicle on coatings applied to vascular grafts |
WO2017158148A1 (en) | 2016-03-17 | 2017-09-21 | Centro Cardiologico Monzino | Polymers and uses thereof in manufacturing of 'living' heart valves |
US10314912B2 (en) | 2012-10-29 | 2019-06-11 | Ariste Medical, Llc | Polymer coating compositions and coated products |
US10729820B2 (en) | 2014-04-22 | 2020-08-04 | Ariste Medical, Llc | Methods and processes for application of drug delivery polymeric coatings |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
GB0315656D0 (en) * | 2003-07-03 | 2003-08-13 | Oxonica Ltd | Metal oxide formulations |
US8431145B2 (en) | 2004-03-19 | 2013-04-30 | Abbott Laboratories | Multiple drug delivery from a balloon and a prosthesis |
US20100030183A1 (en) * | 2004-03-19 | 2010-02-04 | Toner John L | Method of treating vascular disease at a bifurcated vessel using a coated balloon |
US20070027523A1 (en) * | 2004-03-19 | 2007-02-01 | Toner John L | Method of treating vascular disease at a bifurcated vessel using coated balloon |
US20050208093A1 (en) * | 2004-03-22 | 2005-09-22 | Thierry Glauser | Phosphoryl choline coating compositions |
US20070155907A1 (en) * | 2005-12-30 | 2007-07-05 | Zhao Jonathon Z | Biologically active block copolymers |
US7713637B2 (en) * | 2006-03-03 | 2010-05-11 | Advanced Cardiovascular Systems, Inc. | Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer |
US7914806B2 (en) | 2006-06-01 | 2011-03-29 | Boston Scientific Scimed, Inc. | Medical devices having improved performance |
US8685430B1 (en) | 2006-07-14 | 2014-04-01 | Abbott Cardiovascular Systems Inc. | Tailored aliphatic polyesters for stent coatings |
US7713541B1 (en) | 2006-11-21 | 2010-05-11 | Abbott Cardiovascular Systems Inc. | Zwitterionic terpolymers, method of making and use on medical devices |
US10155881B2 (en) * | 2007-05-30 | 2018-12-18 | Abbott Cardiovascular Systems Inc. | Substituted polycaprolactone for coating |
US9737638B2 (en) | 2007-06-20 | 2017-08-22 | Abbott Cardiovascular Systems, Inc. | Polyester amide copolymers having free carboxylic acid pendant groups |
US20090004243A1 (en) | 2007-06-29 | 2009-01-01 | Pacetti Stephen D | Biodegradable triblock copolymers for implantable devices |
US9814553B1 (en) | 2007-10-10 | 2017-11-14 | Abbott Cardiovascular Systems Inc. | Bioabsorbable semi-crystalline polymer for controlling release of drug from a coating |
US20090104241A1 (en) * | 2007-10-23 | 2009-04-23 | Pacetti Stephen D | Random amorphous terpolymer containing lactide and glycolide |
US20090306120A1 (en) * | 2007-10-23 | 2009-12-10 | Florencia Lim | Terpolymers containing lactide and glycolide |
US8679519B2 (en) | 2007-10-23 | 2014-03-25 | Abbott Cardiovascular Systems Inc. | Coating designs for the tailored release of dual drugs from polymeric coatings |
US8642062B2 (en) | 2007-10-31 | 2014-02-04 | Abbott Cardiovascular Systems Inc. | Implantable device having a slow dissolving polymer |
US8128983B2 (en) * | 2008-04-11 | 2012-03-06 | Abbott Cardiovascular Systems Inc. | Coating comprising poly(ethylene glycol)-poly(lactide-glycolide-caprolactone) interpenetrating network |
US20090285873A1 (en) * | 2008-04-18 | 2009-11-19 | Abbott Cardiovascular Systems Inc. | Implantable medical devices and coatings therefor comprising block copolymers of poly(ethylene glycol) and a poly(lactide-glycolide) |
US8916188B2 (en) * | 2008-04-18 | 2014-12-23 | Abbott Cardiovascular Systems Inc. | Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block |
US20090297584A1 (en) * | 2008-04-18 | 2009-12-03 | Florencia Lim | Biosoluble coating with linear over time mass loss |
US8697113B2 (en) * | 2008-05-21 | 2014-04-15 | Abbott Cardiovascular Systems Inc. | Coating comprising a terpolymer comprising caprolactone and glycolide |
US8697110B2 (en) | 2009-05-14 | 2014-04-15 | Abbott Cardiovascular Systems Inc. | Polymers comprising amorphous terpolymers and semicrystalline blocks |
US8480620B2 (en) * | 2009-12-11 | 2013-07-09 | Abbott Cardiovascular Systems Inc. | Coatings with tunable solubility profile for drug-coated balloon |
US20110144577A1 (en) * | 2009-12-11 | 2011-06-16 | John Stankus | Hydrophilic coatings with tunable composition for drug coated balloon |
US8951595B2 (en) * | 2009-12-11 | 2015-02-10 | Abbott Cardiovascular Systems Inc. | Coatings with tunable molecular architecture for drug-coated balloon |
JP5820676B2 (en) | 2010-10-04 | 2015-11-24 | ローム アンド ハース エレクトロニック マテリアルズ エルエルシーRohm and Haas Electronic Materials LLC | Lower layer composition and method for imaging lower layer |
JP6035017B2 (en) | 2010-10-04 | 2016-11-30 | ローム アンド ハース エレクトロニック マテリアルズ エルエルシーRohm and Haas Electronic Materials LLC | Lower layer composition and method for imaging lower layer |
US8921429B2 (en) | 2010-11-23 | 2014-12-30 | Howard University | Biodegradable stealth polymeric particles fabricated using the macromonomer approach by free radical dispersion polymerization |
US8772355B2 (en) | 2010-11-23 | 2014-07-08 | Howard University | Stealth polymeric particles for delivery of bioactive or diagnostic agents |
US8981025B2 (en) | 2011-02-10 | 2015-03-17 | Corning Incorporated | Polymerizable catonic peptide monomers and polymers |
CN103298535B (en) | 2011-03-25 | 2015-01-28 | 英派尔科技开发有限公司 | Flocculation agents for nanoparticle pollutants |
CN103948970B (en) * | 2014-04-28 | 2016-08-10 | 常州帝斯博医疗用品有限公司 | Hemodialysis extracorporeal circulation pipeline and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020133183A1 (en) * | 2000-09-29 | 2002-09-19 | Lentz David Christian | Coated medical devices |
US6673385B1 (en) * | 2000-05-31 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Methods for polymeric coatings stents |
WO2004009145A1 (en) * | 2002-07-19 | 2004-01-29 | Advanced Cardiovascular Systems, Inc. | Purified polymers for coatings of implantable medical devices |
WO2004101018A1 (en) * | 2003-05-08 | 2004-11-25 | Advanced Cardiovascular Systems, Inc. | Stent coatings comprising hydrophilic additives |
Family Cites Families (298)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR732895A (en) | 1932-10-18 | 1932-09-25 | Consortium Elektrochem Ind | Articles spun in polyvinyl alcohol |
US2386454A (en) | 1940-11-22 | 1945-10-09 | Bell Telephone Labor Inc | High molecular weight linear polyester-amides |
US3849514A (en) | 1967-11-17 | 1974-11-19 | Eastman Kodak Co | Block polyester-polyamide copolymers |
US3773737A (en) | 1971-06-09 | 1973-11-20 | Sutures Inc | Hydrolyzable polymers of amino acid and hydroxy acids |
US4329383A (en) | 1979-07-24 | 1982-05-11 | Nippon Zeon Co., Ltd. | Non-thrombogenic material comprising substrate which has been reacted with heparin |
SU790725A1 (en) | 1979-07-27 | 1983-01-23 | Ордена Ленина Институт Элементоорганических Соединений Ан Ссср | Process for preparing alkylaromatic polyimides |
US4226243A (en) | 1979-07-27 | 1980-10-07 | Ethicon, Inc. | Surgical devices of polyesteramides derived from bis-oxamidodiols and dicarboxylic acids |
SU811750A1 (en) | 1979-08-07 | 1983-09-23 | Институт Физиологии Им.С.И.Бериташвили | Bis-bicarbonates of aliphatic diols as monomers for preparing polyurethanes and process for producing the same |
SU872531A1 (en) | 1979-08-07 | 1981-10-15 | Институт Физиологии Им.И.С.Бериташвили Ан Гсср | Method of producing polyurethans |
SU876663A1 (en) | 1979-11-11 | 1981-10-30 | Институт Физиологии Им. Академика И.С.Бериташвили Ан Гсср | Method of producing polyarylates |
US4343931A (en) | 1979-12-17 | 1982-08-10 | Minnesota Mining And Manufacturing Company | Synthetic absorbable surgical devices of poly(esteramides) |
US4529792A (en) | 1979-12-17 | 1985-07-16 | Minnesota Mining And Manufacturing Company | Process for preparing synthetic absorbable poly(esteramides) |
SU1016314A1 (en) | 1979-12-17 | 1983-05-07 | Институт Физиологии Им.И.С.Бериташвили | Process for producing polyester urethanes |
SU905228A1 (en) | 1980-03-06 | 1982-02-15 | Институт Физиологии Им. Акад.И.С. Бериташвили Ан Гсср | Method for preparing thiourea |
SU1293518A1 (en) | 1985-04-11 | 1987-02-28 | Тбилисский зональный научно-исследовательский и проектный институт типового и экспериментального проектирования жилых и общественных зданий | Installation for testing specimen of cross-shaped structure |
US4656242A (en) | 1985-06-07 | 1987-04-07 | Henkel Corporation | Poly(ester-amide) compositions |
US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4611051A (en) | 1985-12-31 | 1986-09-09 | Union Camp Corporation | Novel poly(ester-amide) hot-melt adhesives |
US4882168A (en) | 1986-09-05 | 1989-11-21 | American Cyanamid Company | Polyesters containing alkylene oxide blocks as drug delivery systems |
JPH0696023B2 (en) | 1986-11-10 | 1994-11-30 | 宇部日東化成株式会社 | Artificial blood vessel and method for producing the same |
US5721131A (en) | 1987-03-06 | 1998-02-24 | United States Of America As Represented By The Secretary Of The Navy | Surface modification of polymers with self-assembled monolayers that promote adhesion, outgrowth and differentiation of biological cells |
US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US6387379B1 (en) | 1987-04-10 | 2002-05-14 | University Of Florida | Biofunctional surface modified ocular implants, surgical instruments, medical devices, prostheses, contact lenses and the like |
US5100689A (en) | 1987-04-10 | 1992-03-31 | University Of Florida | Surface modified surgical instruments, devices, implants, contact lenses and the like |
US4894231A (en) | 1987-07-28 | 1990-01-16 | Biomeasure, Inc. | Therapeutic agent delivery system |
US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
US5019096A (en) | 1988-02-11 | 1991-05-28 | Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
JP2561309B2 (en) | 1988-03-28 | 1996-12-04 | テルモ株式会社 | Medical material and manufacturing method thereof |
US4931287A (en) | 1988-06-14 | 1990-06-05 | University Of Utah | Heterogeneous interpenetrating polymer networks for the controlled release of drugs |
AU614140B2 (en) | 1988-06-28 | 1991-08-22 | Minnesota Mining And Manufacturing Company | Pressure-sensitive adhesive |
US5328471A (en) | 1990-02-26 | 1994-07-12 | Endoluminal Therapeutics, Inc. | Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens |
US4977901A (en) | 1988-11-23 | 1990-12-18 | Minnesota Mining And Manufacturing Company | Article having non-crosslinked crystallized polymer coatings |
IL90193A (en) | 1989-05-04 | 1993-02-21 | Biomedical Polymers Int | Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same |
US5272012A (en) | 1989-06-23 | 1993-12-21 | C. R. Bard, Inc. | Medical apparatus having protective, lubricious coating |
US5971954A (en) | 1990-01-10 | 1999-10-26 | Rochester Medical Corporation | Method of making catheter |
US5496557A (en) | 1990-01-30 | 1996-03-05 | Akzo N.V. | Article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances |
WO1991012846A1 (en) | 1990-02-26 | 1991-09-05 | Slepian Marvin J | Method and apparatus for treatment of tubular organs |
US5292516A (en) | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
US5300295A (en) | 1990-05-01 | 1994-04-05 | Mediventures, Inc. | Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH |
US5306501A (en) | 1990-05-01 | 1994-04-26 | Mediventures, Inc. | Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers |
US5298260A (en) | 1990-05-01 | 1994-03-29 | Mediventures, Inc. | Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality |
WO1991017724A1 (en) | 1990-05-17 | 1991-11-28 | Harbor Medical Devices, Inc. | Medical device polymer |
US6060451A (en) | 1990-06-15 | 2000-05-09 | The National Research Council Of Canada | Thrombin inhibitors based on the amino acid sequence of hirudin |
WO1991019529A1 (en) | 1990-06-15 | 1991-12-26 | Cortrak Medical, Inc. | Drug delivery apparatus and method |
CA2038605C (en) | 1990-06-15 | 2000-06-27 | Leonard Pinchuk | Crack-resistant polycarbonate urethane polymer prostheses and the like |
US5112457A (en) | 1990-07-23 | 1992-05-12 | Case Western Reserve University | Process for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of biomedical implants |
US5455040A (en) | 1990-07-26 | 1995-10-03 | Case Western Reserve University | Anticoagulant plasma polymer-modified substrate |
US6248129B1 (en) | 1990-09-14 | 2001-06-19 | Quanam Medical Corporation | Expandable polymeric stent with memory and delivery apparatus and method |
US5258020A (en) | 1990-09-14 | 1993-11-02 | Michael Froix | Method of using expandable polymeric stent with memory |
US5163952A (en) | 1990-09-14 | 1992-11-17 | Michael Froix | Expandable polymeric stent with memory and delivery apparatus and method |
US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
GB9027793D0 (en) | 1990-12-21 | 1991-02-13 | Ucb Sa | Polyester-amides containing terminal carboxyl groups |
US5330768A (en) | 1991-07-05 | 1994-07-19 | Massachusetts Institute Of Technology | Controlled drug delivery using polymer/pluronic blends |
US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5599352A (en) | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
GB9206736D0 (en) | 1992-03-27 | 1992-05-13 | Sandoz Ltd | Improvements of organic compounds and their use in pharmaceutical compositions |
US5219980A (en) | 1992-04-16 | 1993-06-15 | Sri International | Polymers biodegradable or bioerodiable into amino acids |
DE69325845T2 (en) | 1992-04-28 | 2000-01-05 | Terumo Corp | Thermoplastic polymer composition and medical devices made therefrom |
DE4224401A1 (en) | 1992-07-21 | 1994-01-27 | Pharmatech Gmbh | New biodegradable homo- and co-polymer(s) for pharmaceutical use - produced by polycondensation of prod. from heterolytic cleavage of aliphatic polyester with functionalised (cyclo)aliphatic cpd. |
US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
FR2699168B1 (en) | 1992-12-11 | 1995-01-13 | Rhone Poulenc Chimie | Method of treating a material comprising a polymer by hydrolysis. |
EP0604022A1 (en) | 1992-12-22 | 1994-06-29 | Advanced Cardiovascular Systems, Inc. | Multilayered biodegradable stent and method for its manufacture |
US5464650A (en) | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
US20020055710A1 (en) | 1998-04-30 | 2002-05-09 | Ronald J. Tuch | Medical device for delivering a therapeutic agent and method of preparation |
US5824048A (en) | 1993-04-26 | 1998-10-20 | Medtronic, Inc. | Method for delivering a therapeutic substance to a body lumen |
US5531715A (en) | 1993-05-12 | 1996-07-02 | Target Therapeutics, Inc. | Lubricious catheters |
US5569650A (en) * | 1993-06-11 | 1996-10-29 | Sloan-Kettering Institute For Cancer Research | C-nucleoside isosters of analogs thereof and pharmaceutical compositions |
JPH0767895A (en) | 1993-06-25 | 1995-03-14 | Sumitomo Electric Ind Ltd | Antimicrobial artificial blood vessel and suture yarn for antimicrobial operation |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
EG20321A (en) | 1993-07-21 | 1998-10-31 | Otsuka Pharma Co Ltd | Medical material and process for producing the same |
DE4327024A1 (en) | 1993-08-12 | 1995-02-16 | Bayer Ag | Thermoplastically processable and biodegradable aliphatic polyesteramides |
US5380299A (en) | 1993-08-30 | 1995-01-10 | Med Institute, Inc. | Thrombolytic treated intravascular medical device |
WO1995010989A1 (en) | 1993-10-19 | 1995-04-27 | Scimed Life Systems, Inc. | Intravascular stent pump |
US5723004A (en) | 1993-10-21 | 1998-03-03 | Corvita Corporation | Expandable supportive endoluminal grafts |
WO1995019796A1 (en) | 1994-01-21 | 1995-07-27 | Brown University Research Foundation | Biocompatible implants |
US6051576A (en) | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
CA2190121A1 (en) | 1994-03-15 | 1995-09-21 | Edith Mathiowitz | Polymeric gene delivery system |
US5567410A (en) | 1994-06-24 | 1996-10-22 | The General Hospital Corporation | Composotions and methods for radiographic imaging |
US5670558A (en) | 1994-07-07 | 1997-09-23 | Terumo Kabushiki Kaisha | Medical instruments that exhibit surface lubricity when wetted |
US5788979A (en) | 1994-07-22 | 1998-08-04 | Inflow Dynamics Inc. | Biodegradable coating with inhibitory properties for application to biocompatible materials |
US5516881A (en) | 1994-08-10 | 1996-05-14 | Cornell Research Foundation, Inc. | Aminoxyl-containing radical spin labeling in polymers and copolymers |
US5578073A (en) | 1994-09-16 | 1996-11-26 | Ramot Of Tel Aviv University | Thromboresistant surface treatment for biomaterials |
US5485496A (en) | 1994-09-22 | 1996-01-16 | Cornell Research Foundation, Inc. | Gamma irradiation sterilizing of biomaterial medical devices or products, with improved degradation and mechanical properties |
US5649977A (en) | 1994-09-22 | 1997-07-22 | Advanced Cardiovascular Systems, Inc. | Metal reinforced polymer stent |
FR2724938A1 (en) | 1994-09-28 | 1996-03-29 | Lvmh Rech | POLYMERS FUNCTIONALIZED BY AMINO ACIDS OR AMINO ACID DERIVATIVES, THEIR USE AS SURFACTANTS, IN PARTICULAR, IN COSMETIC COMPOSITIONS AND IN PARTICULAR NAIL POLISH. |
EP0785774B1 (en) | 1994-10-12 | 2001-01-31 | Focal, Inc. | Targeted delivery via biodegradable polymers |
US5579073A (en) * | 1994-11-28 | 1996-11-26 | Ben-Yaacov; Shlomo | Photographic processing system |
US5637113A (en) | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US5569198A (en) | 1995-01-23 | 1996-10-29 | Cortrak Medical Inc. | Microporous catheter |
US6017577A (en) | 1995-02-01 | 2000-01-25 | Schneider (Usa) Inc. | Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices |
US5919570A (en) | 1995-02-01 | 1999-07-06 | Schneider Inc. | Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a poly(N-vinylpyrrolidone) polymer hydrogel, coated polymer and metal substrate materials, and coated medical devices |
US5702754A (en) | 1995-02-22 | 1997-12-30 | Meadox Medicals, Inc. | Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with such coatings |
US6231600B1 (en) | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
US5869127A (en) | 1995-02-22 | 1999-02-09 | Boston Scientific Corporation | Method of providing a substrate with a bio-active/biocompatible coating |
US5854376A (en) | 1995-03-09 | 1998-12-29 | Sekisui Kaseihin Kogyo Kabushiki Kaisha | Aliphatic ester-amide copolymer resins |
US5605696A (en) | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
US6120536A (en) | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US20020091433A1 (en) | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
US5837313A (en) | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
RU2169742C2 (en) | 1995-04-19 | 2001-06-27 | Катаока Казунори | Heterotelochelate block copolymer and method of preparation thereof |
US5674242A (en) | 1995-06-06 | 1997-10-07 | Quanam Medical Corporation | Endoprosthetic device with therapeutic compound |
US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
US5820917A (en) | 1995-06-07 | 1998-10-13 | Medtronic, Inc. | Blood-contacting medical device and method |
WO1998017331A1 (en) | 1995-06-07 | 1998-04-30 | Cook Incorporated | Silver implantable medical device |
US5609629A (en) | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US7611533B2 (en) | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
US7550005B2 (en) | 1995-06-07 | 2009-06-23 | Cook Incorporated | Coated implantable medical device |
CA2223889A1 (en) | 1995-06-07 | 1996-12-19 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6010530A (en) | 1995-06-07 | 2000-01-04 | Boston Scientific Technology, Inc. | Self-expanding endoluminal prosthesis |
CA2178541C (en) | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
US5667767A (en) | 1995-07-27 | 1997-09-16 | Micro Therapeutics, Inc. | Compositions for use in embolizing blood vessels |
US5877224A (en) | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
US5723219A (en) | 1995-12-19 | 1998-03-03 | Talison Research | Plasma deposited film networks |
US5658995A (en) | 1995-11-27 | 1997-08-19 | Rutgers, The State University | Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide) |
DE19545678A1 (en) | 1995-12-07 | 1997-06-12 | Goldschmidt Ag Th | Copolymers of polyamino acid esters |
DK2111876T3 (en) | 1995-12-18 | 2011-12-12 | Angiodevice Internat Gmbh | Crosslinked polymer preparations and methods for their use |
US6033582A (en) | 1996-01-22 | 2000-03-07 | Etex Corporation | Surface modification of medical implants |
US6054553A (en) | 1996-01-29 | 2000-04-25 | Bayer Ag | Process for the preparation of polymers having recurring agents |
EP0796634B1 (en) | 1996-03-21 | 2005-11-16 | BIOTRONIK Mess- und Therapiegeräte GmbH & Co Ingenieurbüro Berlin | Implantable stimulation electrode |
US5932299A (en) | 1996-04-23 | 1999-08-03 | Katoot; Mohammad W. | Method for modifying the surface of an object |
US5955509A (en) | 1996-05-01 | 1999-09-21 | Board Of Regents, The University Of Texas System | pH dependent polymer micelles |
US5610241A (en) | 1996-05-07 | 1997-03-11 | Cornell Research Foundation, Inc. | Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers |
EP0819751A1 (en) * | 1996-05-20 | 1998-01-21 | Fluor Corporation | Vapour recovery system |
JP2000511161A (en) | 1996-05-24 | 2000-08-29 | アンジオテック ファーマシュウティカルズ,インコーポレイテッド | Compositions and methods for treating or preventing diseases of the body passages |
US5876433A (en) | 1996-05-29 | 1999-03-02 | Ethicon, Inc. | Stent and method of varying amounts of heparin coated thereon to control treatment |
US5874165A (en) | 1996-06-03 | 1999-02-23 | Gore Enterprise Holdings, Inc. | Materials and method for the immobilization of bioactive species onto polymeric subtrates |
NL1003459C2 (en) | 1996-06-28 | 1998-01-07 | Univ Twente | Copoly (ester amides) and copoly (ester urethanes). |
US5711958A (en) | 1996-07-11 | 1998-01-27 | Life Medical Sciences, Inc. | Methods for reducing or eliminating post-surgical adhesion formation |
US5830178A (en) | 1996-10-11 | 1998-11-03 | Micro Therapeutics, Inc. | Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide |
US6060518A (en) | 1996-08-16 | 2000-05-09 | Supratek Pharma Inc. | Polymer compositions for chemotherapy and methods of treatment using the same |
AU4090997A (en) | 1996-08-30 | 1998-03-19 | Helix Medical Corporation | Medical devices having microbial resistant material properties |
US5783657A (en) | 1996-10-18 | 1998-07-21 | Union Camp Corporation | Ester-terminated polyamides of polymerized fatty acids useful in formulating transparent gels in low polarity liquids |
US6530951B1 (en) | 1996-10-24 | 2003-03-11 | Cook Incorporated | Silver implantable medical device |
US6120491A (en) | 1997-11-07 | 2000-09-19 | The State University Rutgers | Biodegradable, anionic polymers derived from the amino acid L-tyrosine |
US5980972A (en) | 1996-12-20 | 1999-11-09 | Schneider (Usa) Inc | Method of applying drug-release coatings |
US5997517A (en) | 1997-01-27 | 1999-12-07 | Sts Biopolymers, Inc. | Bonding layers for medical device surface coatings |
WO1998032779A1 (en) | 1997-01-28 | 1998-07-30 | United States Surgical Corporation | Polyesteramide, its preparation and surgical devices fabricated therefrom |
DE69828387T2 (en) | 1997-01-28 | 2005-12-08 | United States Surgical Corp., Norwalk | POLYESTERAMIDE, ITS PRESENTATION AND SURGICAL FABRICATED SURGICAL ARTICLES |
DE69826639T2 (en) | 1997-01-28 | 2005-10-06 | United States Surgical Corp., Norwalk | SURGICAL ARTICLES MADE FROM POLYESTERAMIDES WITH GROUPS DERIVED FROM AMINO ACIDS AND ALTERNATIVELY WITH GROUPS DERIVED FROM ALPHA HYDROXYLIC ACIDS |
WO1998036784A1 (en) | 1997-02-20 | 1998-08-27 | Cook Incorporated | Coated implantable medical device |
US6240616B1 (en) | 1997-04-15 | 2001-06-05 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a medicated porous metal prosthesis |
EP0975691B1 (en) | 1997-04-21 | 2010-10-13 | California Institute Of Technology | Multifunctional polymeric coatings |
US5879697A (en) | 1997-04-30 | 1999-03-09 | Schneider Usa Inc | Drug-releasing coatings for medical devices |
US6159978A (en) | 1997-05-28 | 2000-12-12 | Aventis Pharmaceuticals Product, Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6180632B1 (en) | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6245760B1 (en) | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6056993A (en) | 1997-05-30 | 2000-05-02 | Schneider (Usa) Inc. | Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel |
US6110483A (en) * | 1997-06-23 | 2000-08-29 | Sts Biopolymers, Inc. | Adherent, flexible hydrogel and medicated coatings |
EA200000087A1 (en) | 1997-07-01 | 2000-08-28 | Атеродженикс, Инк. | EFFICIENCY EFFICIENCY IMPROVEMENT OF HYPERPROLIFERATIVE STATE THERAPY WITH THE HELP OF ANTIOXIDANT |
US6211249B1 (en) | 1997-07-11 | 2001-04-03 | Life Medical Sciences, Inc. | Polyester polyether block copolymers |
US5980928A (en) | 1997-07-29 | 1999-11-09 | Terry; Paul B. | Implant for preventing conjunctivitis in cattle |
AU8901798A (en) | 1997-08-08 | 1999-03-01 | Procter & Gamble Company, The | Laundry detergent compositions with amino acid based polymers to provide appearance and integrity benefits to fabrics laundered therewith |
US6121027A (en) | 1997-08-15 | 2000-09-19 | Surmodics, Inc. | Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups |
US6120788A (en) | 1997-10-16 | 2000-09-19 | Bioamide, Inc. | Bioabsorbable triglycolic acid poly(ester-amide)s |
US6015541A (en) | 1997-11-03 | 2000-01-18 | Micro Therapeutics, Inc. | Radioactive embolizing compositions |
US6221425B1 (en) | 1998-01-30 | 2001-04-24 | Advanced Cardiovascular Systems, Inc. | Lubricious hydrophilic coating for an intracorporeal medical device |
US6110188A (en) | 1998-03-09 | 2000-08-29 | Corvascular, Inc. | Anastomosis method |
US6258371B1 (en) | 1998-04-03 | 2001-07-10 | Medtronic Inc | Method for making biocompatible medical article |
US20030040790A1 (en) | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
US20010029351A1 (en) | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
US7658727B1 (en) | 1998-04-20 | 2010-02-09 | Medtronic, Inc | Implantable medical device with enhanced biocompatibility and biostability |
US20020188037A1 (en) | 1999-04-15 | 2002-12-12 | Chudzik Stephen J. | Method and system for providing bioactive agent release coating |
EP1555036B1 (en) | 1998-04-27 | 2010-05-05 | Surmodics Inc. | Bioactive agent release coating |
US6113629A (en) | 1998-05-01 | 2000-09-05 | Micrus Corporation | Hydrogel for the therapeutic treatment of aneurysms |
KR100314496B1 (en) | 1998-05-28 | 2001-11-22 | 윤동진 | Non-thrombogenic heparin derivatives, process for preparation and use thereof |
WO1999063981A2 (en) | 1998-06-11 | 1999-12-16 | Cerus Corporation | Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells |
US6153252A (en) | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
AU4645299A (en) * | 1998-07-08 | 2000-02-01 | Advanced Biocompatible Coatings Inc. | Biocompatible metallic stents with hydroxy methacrylate coating |
WO2000010622A1 (en) | 1998-08-20 | 2000-03-02 | Cook Incorporated | Coated implantable medical device |
US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
US6335029B1 (en) | 1998-08-28 | 2002-01-01 | Scimed Life Systems, Inc. | Polymeric coatings for controlled delivery of active agents |
CA2338788A1 (en) | 1998-09-02 | 2000-03-09 | Scimed Life Systems, Inc. | Drug delivery device for stent |
WO2000018446A1 (en) | 1998-09-25 | 2000-04-06 | Cathnet-Science S.A. | Multi-layered sleeve for intravascular expandable device |
US6011125A (en) | 1998-09-25 | 2000-01-04 | General Electric Company | Amide modified polyesters |
US6530950B1 (en) | 1999-01-12 | 2003-03-11 | Quanam Medical Corporation | Intraluminal stent having coaxial polymer member |
ATE226837T1 (en) * | 1999-01-12 | 2002-11-15 | Quanam Medical Corp | POLYMER COMPOSITION FOR INTRALUMINAL STENT |
WO2000041738A1 (en) | 1999-01-12 | 2000-07-20 | Quanam Medical Corporation | Polymer compositions for intraluminal stent |
US6419692B1 (en) | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
US6143354A (en) | 1999-02-08 | 2000-11-07 | Medtronic Inc. | One-step method for attachment of biomolecules to substrate surfaces |
WO2000064506A1 (en) | 1999-04-23 | 2000-11-02 | Agion Technologies, L.L.C. | Stent having antimicrobial agent |
US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
US6283947B1 (en) | 1999-07-13 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Local drug delivery injection catheter |
US6494862B1 (en) | 1999-07-13 | 2002-12-17 | Advanced Cardiovascular Systems, Inc. | Substance delivery apparatus and a method of delivering a therapeutic substance to an anatomical passageway |
US6177523B1 (en) | 1999-07-14 | 2001-01-23 | Cardiotech International, Inc. | Functionalized polyurethanes |
FI19991852A (en) | 1999-09-01 | 2001-03-01 | Yli Urpo Antti | New multilayer material with a biologically active agent, and its preparation |
US6503556B2 (en) | 2000-12-28 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Methods of forming a coating for a prosthesis |
US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
EP1214108B1 (en) | 1999-09-03 | 2007-01-10 | Advanced Cardiovascular Systems, Inc. | A porous prosthesis and a method of depositing substances into the pores |
US6749626B1 (en) | 2000-03-31 | 2004-06-15 | Advanced Cardiovascular Systems, Inc. | Actinomycin D for the treatment of vascular disease |
US6713119B2 (en) | 1999-09-03 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Biocompatible coating for a prosthesis and a method of forming the same |
US20040029952A1 (en) | 1999-09-03 | 2004-02-12 | Yung-Ming Chen | Ethylene vinyl alcohol composition and coating |
US6503954B1 (en) | 2000-03-31 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Biocompatible carrier containing actinomycin D and a method of forming the same |
US6759054B2 (en) | 1999-09-03 | 2004-07-06 | Advanced Cardiovascular Systems, Inc. | Ethylene vinyl alcohol composition and coating |
US6287628B1 (en) | 1999-09-03 | 2001-09-11 | Advanced Cardiovascular Systems, Inc. | Porous prosthesis and a method of depositing substances into the pores |
US6379381B1 (en) | 1999-09-03 | 2002-04-30 | Advanced Cardiovascular Systems, Inc. | Porous prosthesis and a method of depositing substances into the pores |
US6203551B1 (en) | 1999-10-04 | 2001-03-20 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implant device |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US6251136B1 (en) | 1999-12-08 | 2001-06-26 | Advanced Cardiovascular Systems, Inc. | Method of layering a three-coated stent using pharmacological and polymeric agents |
US6613432B2 (en) | 1999-12-22 | 2003-09-02 | Biosurface Engineering Technologies, Inc. | Plasma-deposited coatings, devices and methods |
US6908624B2 (en) | 1999-12-23 | 2005-06-21 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US6283949B1 (en) | 1999-12-27 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Refillable implantable drug delivery pump |
AU2599501A (en) | 1999-12-29 | 2001-07-09 | Advanced Cardiovascular Systems Inc. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
AU2623201A (en) | 1999-12-30 | 2001-07-16 | Kam W Leong | Controlled delivery of therapeutic agents by insertable medical devices |
JP4473390B2 (en) | 2000-01-07 | 2010-06-02 | 川澄化学工業株式会社 | Stent and stent graft |
EP1421855A3 (en) | 2000-01-11 | 2004-07-14 | Intralytix Inc. | Method and device for sanitation using bacteriophages |
US6527801B1 (en) | 2000-04-13 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Biodegradable drug delivery material for stent |
US20020007215A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US20020005206A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Antiproliferative drug and delivery device |
US20020007214A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020007213A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6395326B1 (en) | 2000-05-31 | 2002-05-28 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for depositing a coating onto a surface of a prosthesis |
US6585765B1 (en) | 2000-06-29 | 2003-07-01 | Advanced Cardiovascular Systems, Inc. | Implantable device having substances impregnated therein and a method of impregnating the same |
US20020077693A1 (en) | 2000-12-19 | 2002-06-20 | Barclay Bruce J. | Covered, coiled drug delivery stent and method |
AU2001279288A1 (en) | 2000-07-06 | 2002-01-21 | Biosurface Engineering Technologies, Inc. | Drug diffusion coatings, applications and methods |
US6555157B1 (en) | 2000-07-25 | 2003-04-29 | Advanced Cardiovascular Systems, Inc. | Method for coating an implantable device and system for performing the method |
WO2002009768A2 (en) | 2000-07-27 | 2002-02-07 | Rutgers, The State University | Therapeutic polyesters and polyamides |
US6451373B1 (en) | 2000-08-04 | 2002-09-17 | Advanced Cardiovascular Systems, Inc. | Method of forming a therapeutic coating onto a surface of an implantable prosthesis |
JP2004520088A (en) * | 2000-08-15 | 2004-07-08 | サーモディックス,インコーポレイティド | Drug admixture matrix |
US6503538B1 (en) | 2000-08-30 | 2003-01-07 | Cornell Research Foundation, Inc. | Elastomeric functional biodegradable copolyester amides and copolyester urethanes |
US6585926B1 (en) | 2000-08-31 | 2003-07-01 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a porous balloon |
WO2002026162A2 (en) | 2000-09-26 | 2002-04-04 | Advanced Cardiovascular Systems, Inc. | A method of loading a substance onto an implantable device |
US6716444B1 (en) | 2000-09-28 | 2004-04-06 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
US6254632B1 (en) | 2000-09-28 | 2001-07-03 | Advanced Cardiovascular Systems, Inc. | Implantable medical device having protruding surface structures for drug delivery and cover attachment |
US6746773B2 (en) | 2000-09-29 | 2004-06-08 | Ethicon, Inc. | Coatings for medical devices |
US7261735B2 (en) | 2001-05-07 | 2007-08-28 | Cordis Corporation | Local drug delivery devices and methods for maintaining the drug coatings thereon |
US20020051730A1 (en) | 2000-09-29 | 2002-05-02 | Stanko Bodnar | Coated medical devices and sterilization thereof |
US20020111590A1 (en) | 2000-09-29 | 2002-08-15 | Davila Luis A. | Medical devices, drug coatings and methods for maintaining the drug coatings thereon |
US6506437B1 (en) | 2000-10-17 | 2003-01-14 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device having depots formed in a surface thereof |
US6558733B1 (en) | 2000-10-26 | 2003-05-06 | Advanced Cardiovascular Systems, Inc. | Method for etching a micropatterned microdepot prosthesis |
US6783793B1 (en) | 2000-10-26 | 2004-08-31 | Advanced Cardiovascular Systems, Inc. | Selective coating of medical devices |
US6758859B1 (en) | 2000-10-30 | 2004-07-06 | Kenny L. Dang | Increased drug-loading and reduced stress drug delivery device |
ATE369817T1 (en) | 2000-12-22 | 2007-09-15 | Avantec Vascular Corp | DEVICE FOR DELIVERING THERAPEUTIC ACTIVE INGREDIENTS |
US7077859B2 (en) | 2000-12-22 | 2006-07-18 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US6824559B2 (en) | 2000-12-22 | 2004-11-30 | Advanced Cardiovascular Systems, Inc. | Ethylene-carboxyl copolymers as drug delivery matrices |
US20020082679A1 (en) | 2000-12-22 | 2002-06-27 | Avantec Vascular Corporation | Delivery or therapeutic capable agents |
US6544543B1 (en) | 2000-12-27 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Periodic constriction of vessels to treat ischemic tissue |
US6663662B2 (en) | 2000-12-28 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Diffusion barrier layer for implantable devices |
US6540776B2 (en) | 2000-12-28 | 2003-04-01 | Advanced Cardiovascular Systems, Inc. | Sheath for a prosthesis and methods of forming the same |
US20020087123A1 (en) | 2001-01-02 | 2002-07-04 | Hossainy Syed F.A. | Adhesion of heparin-containing coatings to blood-contacting surfaces of medical devices |
US6645195B1 (en) | 2001-01-05 | 2003-11-11 | Advanced Cardiovascular Systems, Inc. | Intraventricularly guided agent delivery system and method of use |
US6544223B1 (en) | 2001-01-05 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Balloon catheter for delivering therapeutic agents |
US6544582B1 (en) | 2001-01-05 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for coating an implantable device |
US6740040B1 (en) | 2001-01-30 | 2004-05-25 | Advanced Cardiovascular Systems, Inc. | Ultrasound energy driven intraventricular catheter to treat ischemia |
US20030032767A1 (en) | 2001-02-05 | 2003-02-13 | Yasuhiro Tada | High-strength polyester-amide fiber and process for producing the same |
WO2002064014A2 (en) | 2001-02-09 | 2002-08-22 | Endoluminal Therapeutics, Inc. | Endomural therapy |
WO2002072014A2 (en) | 2001-03-08 | 2002-09-19 | Volcano Therapeutics, Inc. | Medical devices, compositions and methods for treating vulnerable plaque |
US6623448B2 (en) | 2001-03-30 | 2003-09-23 | Advanced Cardiovascular Systems, Inc. | Steerable drug delivery device |
US6645135B1 (en) | 2001-03-30 | 2003-11-11 | Advanced Cardiovascular Systems, Inc. | Intravascular catheter device and method for simultaneous local delivery of radiation and a therapeutic substance |
US6780424B2 (en) | 2001-03-30 | 2004-08-24 | Charles David Claude | Controlled morphologies in polymer drug for release of drugs from polymer films |
US6625486B2 (en) | 2001-04-11 | 2003-09-23 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for intracellular delivery of an agent |
US6764505B1 (en) | 2001-04-12 | 2004-07-20 | Advanced Cardiovascular Systems, Inc. | Variable surface area stent |
US6712845B2 (en) | 2001-04-24 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Coating for a stent and a method of forming the same |
EP1383504A1 (en) | 2001-04-26 | 2004-01-28 | Control Delivery Systems, Inc. | Sustained release drug delivery system containing codrugs |
US6660034B1 (en) | 2001-04-30 | 2003-12-09 | Advanced Cardiovascular Systems, Inc. | Stent for increasing blood flow to ischemic tissues and a method of using the same |
US6656506B1 (en) | 2001-05-09 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Microparticle coated medical device |
US7651695B2 (en) | 2001-05-18 | 2010-01-26 | Advanced Cardiovascular Systems, Inc. | Medicated stents for the treatment of vascular disease |
US6605154B1 (en) | 2001-05-31 | 2003-08-12 | Advanced Cardiovascular Systems, Inc. | Stent mounting device |
US7862495B2 (en) | 2001-05-31 | 2011-01-04 | Advanced Cardiovascular Systems, Inc. | Radiation or drug delivery source with activity gradient to minimize edge effects |
US6743462B1 (en) | 2001-05-31 | 2004-06-01 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for coating implantable devices |
US6666880B1 (en) | 2001-06-19 | 2003-12-23 | Advised Cardiovascular Systems, Inc. | Method and system for securing a coated stent to a balloon catheter |
US6572644B1 (en) | 2001-06-27 | 2003-06-03 | Advanced Cardiovascular Systems, Inc. | Stent mounting device and a method of using the same to coat a stent |
US7247313B2 (en) | 2001-06-27 | 2007-07-24 | Advanced Cardiovascular Systems, Inc. | Polyacrylates coatings for implantable medical devices |
US6695920B1 (en) | 2001-06-27 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Mandrel for supporting a stent and a method of using the mandrel to coat a stent |
US6565659B1 (en) | 2001-06-28 | 2003-05-20 | Advanced Cardiovascular Systems, Inc. | Stent mounting assembly and a method of using the same to coat a stent |
US6673154B1 (en) | 2001-06-28 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Stent mounting device to coat a stent |
US6585755B2 (en) | 2001-06-29 | 2003-07-01 | Advanced Cardiovascular | Polymeric stent suitable for imaging by MRI and fluoroscopy |
US6527863B1 (en) | 2001-06-29 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Support device for a stent and a method of using the same to coat a stent |
US6656216B1 (en) | 2001-06-29 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Composite stent with regioselective material |
US6706013B1 (en) | 2001-06-29 | 2004-03-16 | Advanced Cardiovascular Systems, Inc. | Variable length drug delivery catheter |
EP1273314A1 (en) | 2001-07-06 | 2003-01-08 | Terumo Kabushiki Kaisha | Stent |
US6641611B2 (en) | 2001-11-26 | 2003-11-04 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
US8303651B1 (en) | 2001-09-07 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Polymeric coating for reducing the rate of release of a therapeutic substance from a stent |
US20030083739A1 (en) | 2001-09-24 | 2003-05-01 | Robert Cafferata | Rational drug therapy device and methods |
US7195640B2 (en) | 2001-09-25 | 2007-03-27 | Cordis Corporation | Coated medical devices for the treatment of vulnerable plaque |
US20030059520A1 (en) | 2001-09-27 | 2003-03-27 | Yung-Ming Chen | Apparatus for regulating temperature of a composition and a method of coating implantable devices |
US6753071B1 (en) | 2001-09-27 | 2004-06-22 | Advanced Cardiovascular Systems, Inc. | Rate-reducing membrane for release of an agent |
US20030065377A1 (en) | 2001-09-28 | 2003-04-03 | Davila Luis A. | Coated medical devices |
US20030073961A1 (en) | 2001-09-28 | 2003-04-17 | Happ Dorrie M. | Medical device containing light-protected therapeutic agent and a method for fabricating thereof |
DE60235775D1 (en) | 2001-11-08 | 2010-05-06 | Ziscoat N V | Intraluminal device with a therapeutic agent-containing coating |
US7585516B2 (en) | 2001-11-12 | 2009-09-08 | Advanced Cardiovascular Systems, Inc. | Coatings for drug delivery devices |
US6663880B1 (en) | 2001-11-30 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Permeabilizing reagents to increase drug delivery and a method of local delivery |
US6709514B1 (en) | 2001-12-28 | 2004-03-23 | Advanced Cardiovascular Systems, Inc. | Rotary coating apparatus for coating implantable medical devices |
AU2003225882A1 (en) | 2002-03-20 | 2003-10-08 | Advanced Cardiovascular Systems, Inc. | Biodegradable hydrophobic polymer for stents |
DE10223310A1 (en) | 2002-05-24 | 2003-12-11 | Biotronik Mess & Therapieg | Process for coating implants with a polysaccharide layer |
US7794743B2 (en) | 2002-06-21 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of making the same |
US20040054104A1 (en) | 2002-09-05 | 2004-03-18 | Pacetti Stephen D. | Coatings for drug delivery devices comprising modified poly(ethylene-co-vinyl alcohol) |
US20040063805A1 (en) | 2002-09-19 | 2004-04-01 | Pacetti Stephen D. | Coatings for implantable medical devices and methods for fabrication thereof |
US7087263B2 (en) | 2002-10-09 | 2006-08-08 | Advanced Cardiovascular Systems, Inc. | Rare limiting barriers for implantable medical devices |
CA2519503C (en) * | 2003-02-28 | 2015-04-28 | Biointeractions Ltd. | Drug delivery from a polymer coating on a medical device |
US9114198B2 (en) | 2003-11-19 | 2015-08-25 | Advanced Cardiovascular Systems, Inc. | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same |
US7807722B2 (en) | 2003-11-26 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Biobeneficial coating compositions and methods of making and using thereof |
US8309112B2 (en) * | 2003-12-24 | 2012-11-13 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
WO2005086831A2 (en) | 2004-03-10 | 2005-09-22 | Orbus Medical Technologies, Inc. | Endothelial ligand binding coated medical device |
US20090232863A1 (en) | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers |
-
2004
- 2004-03-31 US US10/815,421 patent/US7758880B2/en not_active Expired - Fee Related
-
2005
- 2005-03-25 JP JP2007506403A patent/JP5687815B2/en not_active Expired - Fee Related
- 2005-03-25 WO PCT/US2005/010186 patent/WO2005097227A1/en active Application Filing
- 2005-03-25 EP EP05730732.4A patent/EP1748806B1/en not_active Not-in-force
-
2010
- 2010-06-18 US US12/819,128 patent/US8647655B2/en not_active Expired - Fee Related
-
2013
- 2013-06-06 US US13/911,572 patent/US8871236B2/en not_active Expired - Fee Related
- 2013-06-06 US US13/911,547 patent/US8986726B2/en not_active Expired - Fee Related
-
2014
- 2014-12-01 JP JP2014242908A patent/JP5934774B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6673385B1 (en) * | 2000-05-31 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Methods for polymeric coatings stents |
US20020133183A1 (en) * | 2000-09-29 | 2002-09-19 | Lentz David Christian | Coated medical devices |
WO2004009145A1 (en) * | 2002-07-19 | 2004-01-29 | Advanced Cardiovascular Systems, Inc. | Purified polymers for coatings of implantable medical devices |
WO2004101018A1 (en) * | 2003-05-08 | 2004-11-25 | Advanced Cardiovascular Systems, Inc. | Stent coatings comprising hydrophilic additives |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006002399A2 (en) * | 2004-06-24 | 2006-01-05 | Surmodics, Inc. | Biodegradable implantable medical devices, methods and systems |
WO2006002399A3 (en) * | 2004-06-24 | 2006-03-16 | Surmodics Inc | Biodegradable implantable medical devices, methods and systems |
US8236338B2 (en) | 2004-07-13 | 2012-08-07 | The University Of Tennessee Research Foundation | Adhesive composition for carrying therapeutic agents as delivery vehicle on coatings applied to vascular grafts |
US8568763B2 (en) | 2004-07-13 | 2013-10-29 | The University Of Tennessee Research Foundation | Compositions and coatings for delivery of therapeutic agents |
US9125970B2 (en) | 2004-07-13 | 2015-09-08 | The University Of Tennessee Research Foundation | Adhesive composition for carrying therapeutic agents as delivery vehicle on coating applied to vascular grafts |
US10314912B2 (en) | 2012-10-29 | 2019-06-11 | Ariste Medical, Llc | Polymer coating compositions and coated products |
US10729820B2 (en) | 2014-04-22 | 2020-08-04 | Ariste Medical, Llc | Methods and processes for application of drug delivery polymeric coatings |
WO2017158148A1 (en) | 2016-03-17 | 2017-09-21 | Centro Cardiologico Monzino | Polymers and uses thereof in manufacturing of 'living' heart valves |
Also Published As
Publication number | Publication date |
---|---|
US20100255058A1 (en) | 2010-10-07 |
EP1748806B1 (en) | 2017-04-19 |
JP5934774B2 (en) | 2016-06-15 |
US8986726B2 (en) | 2015-03-24 |
JP2015042324A (en) | 2015-03-05 |
US20130273234A1 (en) | 2013-10-17 |
EP1748806A1 (en) | 2007-02-07 |
JP2007530239A (en) | 2007-11-01 |
US7758880B2 (en) | 2010-07-20 |
US20130266619A1 (en) | 2013-10-10 |
JP5687815B2 (en) | 2015-03-25 |
US20050169957A1 (en) | 2005-08-04 |
US8647655B2 (en) | 2014-02-11 |
US8871236B2 (en) | 2014-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8871236B2 (en) | Biocompatible polyacrylate compositions for medical applications | |
US7776926B1 (en) | Biocompatible coating for implantable medical devices | |
US9468706B2 (en) | Phosphoryl choline coating compositions | |
EP1784434B1 (en) | Polymers of fluorinated monomers and hydrophilic monomers | |
US8529930B2 (en) | Polymers of fluorinated monomers and hydrocarbon monomers | |
JP5368703B2 (en) | Methacrylate copolymers for medical devices | |
US9517292B2 (en) | Polymer for creating hemocompatible surface | |
JP5959039B2 (en) | Substituted polycaprolactone for coating | |
CA2774036A1 (en) | Coatings comprising bis-(alpha-amino-diol-diester) containing polyesteramide | |
JP5201486B2 (en) | Block copolymer containing mid block of methoxyethyl methacrylate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007506403 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2005730732 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005730732 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005730732 Country of ref document: EP |